Table 5 Complex human traits and diseases associated with variants within the brain enhancers that exhibit evidence of recent selection
Enhancer IDrsIDTraitsMetrics
chr2:219271996-219272374rs921968Mean corpuscular hemoglobin concentrationFST
chr3:181418145-181418802rs34308817Ankle injuryTajima’s D
chr6:30069810-30070038rs1111180Eosinophil percentage of granulocytes, Eosinophil percentage of white cellsnSL (EUR)
chr6:30923441-30923743rs17189763Conotruncal heart defects (maternal effects)nSL (EUR)
chr6:32427743-32428120rs9268831Response to hepatitis B vaccinenSL (AFR, EUR, EAS)
chr6:32427743-32428120rs9268835Type 2 diabetesnSL (AFR, EUR, EAS)
chr6:32577297-32577935rs660895IgA nephropathy, Rheumatoid arthritis, Rheumatoid arthritis (ACPA-negative)nSL (AFR, EUR, EAS)
chr7:130720133-130720826rs10265693Lung cancerFST
chr7:29217860-29218383rs245914Psychosis (atypical), Obesity-related traitsTajima’s D
chr13:110790027-110791241rs641862Obesity-related traitsTajima’s D
chr16:22201170-22202123rs145049847Alzheimer disease and age of onsetTajima’s D
chr16:87856343-87856555rs76069656Triglyceride change in response to fenofibrate in statin-treated type 2 diabetesnSL (EUR)
chr16:87886258-87886670rs68149176Mean corpuscular volume, Mean corpuscular hemoglobinnSL (EUR), FST
chr21:45616099-45616530rs4456788Chronic inflammatory diseases (ankylosing spondylitis, Crohn’s disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)nSL (EAS)